Medroxyprogesterone Acetate (MPA) Enhances HIV-1 Accumulation and Release in Primary Cervical Epithelial Cells by Inhibiting Lysosomal Activity

Medroxyprogesterone acetate (MPA) is one of the most widely used contraceptives in the world. Epidemiologic studies have uncovered a possible link between the use of MPA and an increased risk of HIV-1 transmission. However, the understanding of the mechanism is still limited. Our previous publicatio...

Full description

Bibliographic Details
Main Authors: Xiangxu Jia, Qiujia Shao, Ahsen R. Chaudhry, Ballington L. Kinlock, Michael G. Izban, Hong-Ying Zhang, Fernando Villalta, James E. K. Hildreth, Bindong Liu
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pathogens
Subjects:
MPA
Online Access:https://www.mdpi.com/2076-0817/10/9/1192
Description
Summary:Medroxyprogesterone acetate (MPA) is one of the most widely used contraceptives in the world. Epidemiologic studies have uncovered a possible link between the use of MPA and an increased risk of HIV-1 transmission. However, the understanding of the mechanism is still limited. Our previous publication demonstrated that the lysosomal activity in human vaginal epithelial cells attenuated the trafficking of viral particles during HIV-1 transcytosis. In this study, we show that treating human primary cervical epithelial cells with MPA led to a reduction in lysosomal activity. This reduction caused an increase in the intracellular HIV-1 accumulation and, consequently, an increase in viral release. Our study uncovers a novel mechanism by which MPA enhances HIV-1 release in primary cervical epithelial cells, thus providing vital information for HIV intervention and prevention.
ISSN:2076-0817